From Genes to Therapy
Date: 12.5.2014
See DiaSorin automated cell separation and nucleic acid extraction products at EFI 2014, Stockholm, Sweden – Stand S5
Delegates at the 28th European Immunogenetics and Histocompatibility Conference (EFI) “From Genes to Therapy", to be held at the Stockholm Waterfront Congress Centre from 25-28 June 2014, will be able to view the wide range of automated cell separation and nucleic acid kits available for the LIAISON® Ixt/Arrow instrument on the DiaSorin stand S5 (Level 4/M1).
With a varied programme focussing on recent therapeutic, methodological and diagnostic advances, the EFI 2014 annual conference will be an excellent opportunity to hear from international experts and to view the very latest technology available for immunogenetic and histocompatibility applications.
Visitors to the DiaSorin stand will see at first hand the small footprint, ease-of-use and flexibility of the LIAISON® Ixt/Arrow instrument, which is ideal for both cell separations and nucleic acid extractions in low to medium throughput laboratories. They will also be among the first to see the new LIAISON® Ixt/Arrow CellSep Advanced kit for the automated isolation of cells directly from whole blood or buffy coat. Based on proven magnetic bead technology, CellSep Advanced can isolate up to 3 cell types per sample in just 32 minutes per cell type, offering significant time savings compared to manual cell separation methods.
DiaSorin product specialists will be on hand to answer questions about the LIAISON® Ixt/Arrow products and to explain how the kits are used in applications, such as HLA testing and clinical chimerism analysis.
For further details about EFI 2014 visit www.efi2014.eu. For more information about the LIAISON® Ixt/Arrow instrument, cell separation and extraction kits, come and meet the DiaSorin team on stand number S5, located in the sponsor exhibition area outside the main conference hall, or visit www.diasorin.com.
Pam Simmons, Director (PR agency), Mackintosh Lloyd Ltd
Tiffany Page, Global Marketing Manager, Molecular Infectious Disease, DiaSorin
About DiaSorin
Headquartered in Italy and listed in the FTSE Italia Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”. The molecular division is based in Dublin, Ireland.
